Which has preferable valuation and earnings, ANTX or CLNN?

Clene has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Clene $200K 290.99 -$26.17M -$3.50 N/A

Is ANTX or CLNN more profitable?

Anthem has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Clene -20,063.96% N/A -137.04%

Does the media refer more to ANTX or CLNN?

In the previous week, Anthem and Anthem both had 4 articles in the media. Anthem's average media sentiment score of 0.88 beat Clene's score of 0.41 indicating that Anthem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CLNN or DERM?

Journey Medical has higher revenue and earnings than Clene. Journey Medical is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 290.99 -$26.17M -$3.50 N/A Journey Medical $61.86M 3.44 -$11.43M -$0.22 N/A

Is CLNN or DERM more profitable?

Journey Medical has a net margin of -8.95% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Journey Medical's return on equity. Company Net Margins Return on Equity Return on Assets Clene -20,063.96% N/A -137.04% Journey Medical -8.95% -20.23% -6.60%

Does the media favor CLNN or DERM?

In the previous week, Clene and Clene both had 4 articles in the media. Journey Medical's average media sentiment score of 0.59 beat Clene's score of 0.41 indicating that Journey Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SIGA or CLNN?

Clene has a consensus target price of $33.25, suggesting a potential upside of 634.16%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Is SIGA or CLNN more profitable?

Siga Technologies has a net margin of -5.19% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Siga Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Siga Technologies -5.19% -1.55% -1.32% Clene -20,063.96% N/A -137.04%

Is SLGL or CLNN more profitable?

Sol-Gel Technologies has a net margin of -910.14% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Sol-Gel Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies -910.14% -44.05% -36.96% Clene -20,063.96% N/A -137.04%

Does the media favor SLGL or CLNN?

In the previous week, Sol-Gel Technologies had 1 more articles in the media than Clene. MarketBeat recorded 5 mentions for Sol-Gel Technologies and 4 mentions for Clene. Sol-Gel Technologies' average media sentiment score of 0.80 beat Clene's score of 0.41 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CRDL or CLNN more profitable?

Cardiol Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Clene -20,063.96% N/A -137.04%

Does the media refer more to CRDL or CLNN?

In the previous week, Clene had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Clene and 2 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.11 beat Clene's score of 0.41 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Clene (CLNN) Competitors

$4.53 +0.09 (+2.00%)

As of 01:52 PM Eastern

Compare

CLNN vs. ANTX, DERM, SIGA, SLGL, and CRDL

Should you buy Clene stock or one of its competitors? Clene's main competitors and comparable companies include Anthem (ANTX), Journey Medical (DERM), Siga Technologies (SIGA), Sol-Gel Technologies (SLGL), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clene compare to Anthem?

Anthem (NASDAQ:ANTX) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Clene has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Clene	$200K	290.99	-$26.17M	-$3.50	N/A

Anthem presently has a consensus price target of $9.00, indicating a potential upside of 55.31%. Clene has a consensus price target of $33.25, indicating a potential upside of 634.16%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Anthem has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

90.5% of Anthem shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anthem has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Clene	-20,063.96%	N/A	-137.04%

In the previous week, Anthem and Anthem both had 4 articles in the media. Anthem's average media sentiment score of 0.88 beat Clene's score of 0.41 indicating that Anthem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Clene beats Anthem on 9 of the 14 factors compared between the two stocks.

How does Clene compare to Journey Medical?

Clene (NASDAQ:CLNN) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Journey Medical has higher revenue and earnings than Clene. Journey Medical is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	290.99	-$26.17M	-$3.50	N/A
Journey Medical	$61.86M	3.44	-$11.43M	-$0.22	N/A

Clene has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Clene presently has a consensus target price of $33.25, indicating a potential upside of 634.16%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 85.92%. Given Clene's stronger consensus rating and higher possible upside, equities analysts clearly believe Clene is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Journey Medical has a net margin of -8.95% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-20,063.96%	N/A	-137.04%
Journey Medical	-8.95%	-20.23%	-6.60%

In the previous week, Clene and Clene both had 4 articles in the media. Journey Medical's average media sentiment score of 0.59 beat Clene's score of 0.41 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

23.3% of Clene shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Clene beats Journey Medical on 8 of the 15 factors compared between the two stocks.

How does Clene compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Clene had 3 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Clene and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.89 beat Clene's score of 0.41 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Very Positive
Clene	Neutral

Siga Technologies has a net margin of -5.19% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Clene	-20,063.96%	N/A	-137.04%

Siga Technologies has higher revenue and earnings than Clene. Siga Technologies is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.33	$23.28M	-$0.05	N/A
Clene	$200K	290.99	-$26.17M	-$3.50	N/A

Clene has a consensus target price of $33.25, suggesting a potential upside of 634.16%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Siga Technologies has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

Siga Technologies and Clene tied by winning 8 of the 16 factors compared between the two stocks.

How does Clene compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Clene has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

In the previous week, Sol-Gel Technologies had 1 more articles in the media than Clene. MarketBeat recorded 5 mentions for Sol-Gel Technologies and 4 mentions for Clene. Sol-Gel Technologies' average media sentiment score of 0.80 beat Clene's score of 0.41 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sol-Gel Technologies has higher revenue and earnings than Clene. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	11.49	-$6.13M	-$5.64	N/A
Clene	$200K	290.99	-$26.17M	-$3.50	N/A

Sol-Gel Technologies currently has a consensus price target of $197.50, indicating a potential upside of 149.11%. Clene has a consensus price target of $33.25, indicating a potential upside of 634.16%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Sol-Gel Technologies has a net margin of -910.14% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Clene	-20,063.96%	N/A	-137.04%

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Sol-Gel Technologies beats Clene on 10 of the 17 factors compared between the two stocks.

How does Clene compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Cardiol Therapeutics has higher earnings, but lower revenue than Clene. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Clene	$200K	290.99	-$26.17M	-$3.50	N/A

Cardiol Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Clene	-20,063.96%	N/A	-137.04%

In the previous week, Clene had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 4 mentions for Clene and 2 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.11 beat Clene's score of 0.41 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cardiol Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 349.44%. Clene has a consensus price target of $33.25, suggesting a potential upside of 634.16%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Clene beats Cardiol Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Clene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLNN vs. The Competition

Export

Metric	Clene	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.20M	$12.41B	$7.30B	$12.76B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-1.29	783.02	272.80	24.16
Price / Sales	290.99	761.13	626.81	98.22
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	-2.35	12.03	13.14	6.23
Net Income	-$26.17M	$2.83B	$3.47B	$348.07M
7 Day Performance	8.09%	1.92%	1.22%	0.63%
1 Month Performance	-15.97%	6.14%	8.61%	4.81%
1 Year Performance	-15.82%	8.13%	26.08%	16.86%

Clene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLNN Clene	2.3521 of 5 stars	$4.53 +2.0%	$33.25 +634.2%	-16.7%	$58.20M	$200K	N/A	100
ANTX Anthem	2.3914 of 5 stars	$5.63 -3.1%	$9.00 +59.9%	+403.6%	$219.25M	N/A	N/A	N/A
DERM Journey Medical	1.9203 of 5 stars	$7.91 +2.1%	$14.00 +77.0%	+1.8%	$218.74M	$61.86M	N/A	90
SIGA Siga Technologies	0.4402 of 5 stars	$2.94 -3.3%	N/A	-65.1%	$218.42M	$94.57M	N/A	40
SLGL Sol-Gel Technologies	4.18 of 5 stars	$77.39 -0.4%	$197.50 +155.2%	+289.1%	$218.41M	$19.39M	N/A	50	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLNN) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clene (CLNN) Competitors

CLNN vs. ANTX, DERM, SIGA, SLGL, and CRDL

How does Clene compare to Anthem?

Summary

How does Clene compare to Journey Medical?

Summary

How does Clene compare to Siga Technologies?

Summary

How does Clene compare to Sol-Gel Technologies?

Summary

How does Clene compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clene (CLNN) Competitors

CLNN vs. ANTX, DERM, SIGA, SLGL, and CRDL

How does Clene compare to Anthem?

Which has preferable valuation and earnings, ANTX or CLNN?

Do analysts rate ANTX or CLNN?

Which has more volatility & risk, ANTX or CLNN?

Do institutionals and insiders believe in ANTX or CLNN?

Is ANTX or CLNN more profitable?

Does the media refer more to ANTX or CLNN?

Summary

How does Clene compare to Journey Medical?

Which has higher valuation and earnings, CLNN or DERM?

Which has more risk and volatility, CLNN or DERM?

Do analysts prefer CLNN or DERM?

Is CLNN or DERM more profitable?

Does the media favor CLNN or DERM?

Do institutionals and insiders believe in CLNN or DERM?

Summary

How does Clene compare to Siga Technologies?

Does the media prefer SIGA or CLNN?

Is SIGA or CLNN more profitable?

Which has better earnings and valuation, SIGA or CLNN?

Do analysts recommend SIGA or CLNN?

Do insiders & institutionals hold more shares of SIGA or CLNN?

Which has more volatility and risk, SIGA or CLNN?

Summary

How does Clene compare to Sol-Gel Technologies?

Which has more risk and volatility, SLGL or CLNN?

Does the media favor SLGL or CLNN?

Which has higher valuation and earnings, SLGL or CLNN?

Do analysts prefer SLGL or CLNN?

Is SLGL or CLNN more profitable?

Do institutionals and insiders believe in SLGL or CLNN?

Summary

How does Clene compare to Cardiol Therapeutics?

Which has better valuation & earnings, CRDL or CLNN?

Which has more volatility & risk, CRDL or CLNN?

Is CRDL or CLNN more profitable?

Does the media refer more to CRDL or CLNN?

Do institutionals and insiders have more ownership in CRDL or CLNN?

Do analysts recommend CRDL or CLNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools